|Follow us :|
Luai Al Bakour
El Temamy Pharmacy
Akoni Hijyen Teknolojileri Sanayi ve Dış Ticaret LTD. ŞTİ
Britton Chance Center for Biomedical Photonics
Arabian Trade Center - ATC
Medical Facility (32206):
Legality International. (Pvt.) Ltd.
MainYou must sign in to use this servcie
Feedback - Please use the form below to send your query or comment
You must sign in to use this servcie
Fluid and electrolyte depletion
This medicine should not be used if: - Hyperhydration predominantly extracellular - Congestive heart failure; - Severe renal impairment (creatinine clearance below 30 ml/min/1, 73 sqm); - Hyperkalemia; - Hypercalcemia; - Metabolic alkalosis; - In combination with digitalis and diuretics (amiloride, potassium canrenoate, spironolactone, triamterene, alone or combined) (see Interactions). Do not inject intramuscularly. RECOMMENDED: Concomitant use not recommended: angiotensin converting enzyme (ACE) inhibitors, quinidine, tacrolimus.
Potential side effects (chills, nausea, vomiting ...) may appear in severe renal impairment, overdose or too rapid rate of administration.
INTERACTIONS RELATED TO CALCIUM: Contra-indication: Digitalis: serious cardiac arrhythmias or death. ASSOCIATION TO TAKE INTO ACCOUNT: Thiazide Diuretics: risk of hypercalcemia by decreasing the urinary excretion of calcium. INTERACTIONS RELATED TO POTASSIUM: Contra-indication: Diuretics (amiloride, potassium canrenoate, spironolactone, triamterene) alone or in combination: hyperkalemia is potentially lethal, especially in renal impairment (additive effects hyperkaliémiants). Combination not recommended: - Angiotensin-converting enzyme (ACE): hyperkalemia is potentially lethal, especially in renal impairment (additive effects hyperkaliémiants). - Tacrolimus: hyperkalemia is potentially lethal, especially in renal impairment (additive effects hyperkaliémiants). INTERACTIONS RELATED TO MAGNESIUM: Combination not recommended: Quinidine: Increased plasma levels of quinidine and risk of overdose (decreased renal excretion of quinidine by alkalinization of urine). INCOMPATIBILITY WITH CERTAIN ANTIBIOTICS Physical chemistry: Amphotericin B (IV).
THIS SOLUTION MUST BE ABSOLUTELY diluted before use. - This solution should not be injected intramuscularly. - Consider the presence of sodium, potassium and magnesium. - The use of this solution is not recommended if concurrent therapy with ACE inhibitors, quinidine and tacrolimus (see Interactions). - Before use, check the integrity of the container and its sealing. Check the clarity and color of the solution. - In addition: . risk of complications related to volume of solution and the amount of electrolytes that is administered; . risk of overloading the cardiovascular system with pulmonary edema especially in patients predisposed . this solution containing magnesium lactate, the infusion may cause metabolic alkalosis due to the presence of lactate ions. . in subjects with hepatic impairment, this solution may not produce its alkalizing action, lactate metabolism may be altered. . if concomitant blood transfusion, and because of the presence of calcium, this solution should not be administered in the same infusion set because of the risk of clotting. - The use of this solution requires increased biological and clinical monitoring of patients, especially if: . edema with sodium retention, . corticosteroids and their derivatives. - This solution, containing potassium, serum potassium should be monitored particularly in patients with a risk of hyperkalemia, such as chronic renal failure. - Pregnancy: Clinically, the use of most cations in the composition of IONITAN, in a limited number of pregnancies, has apparently revealed no effect of malformation or fetotoxic particular date. However, further studies are needed to evaluate the consequences of exposure during pregnancy. Consequently, the use of IONITAN should be considered during pregnancy only if necessary. - Incompatibilities physicochemical It falls to the doctor to assess the incompatibility of a drug additive vis-à-vis the electrolyte solution, by controlling a change of color and / or possible formation of precipitate, or insoluble complex crystals. Also refer to the instructions accompanying the product to add. Before adding a drug, whether the pH range for which it is effective corresponds to that of the electrolyte solution. When a drug is added to this solution, the mixture should be administered immediately.
SOLUTION FOR INJECTION
Dosage and AdministrationYou must sign in to use this servcie
Technical DescriptionYou must sign in to use this servcie
Yaser Habrawi , F.R.C.S.Ed
Dr. Talal Sabouni
Dr. Tahsin Martini
Dr. Hani Najjar
Samir Moussa M.D.
Dr . Dirar Abboud
Dr. Faisal Dibsi
Dr. Samer Al-Jneidy